ALS setback trims Novartis pipeline optionality

What happened

Novartis halted development of an experimental ALS drug after it failed in a mid-stage study, marking another setback in a year already pressured by Entresto generic erosion and shrinking margins. This failure is not among the company's core late-stage catalysts—Pluvicto mHSPC approval, pelacarsen outcomes, remibrutinib MS data, and del-desiran Phase III—but it adds to a growing list of pipeline disappointments that undermine the premium valuation. The stock trades at 23.1x forward earnings with limited margin of safety, as H1 2026 sales were down 2% in constant currency and operating margin fell to 32.6%. While the halted ALS program had not been highlighted as a major value driver, its failure reinforces concerns about execution risk ahead of critical H2 2026 readouts. Investors now face a binary setup: successful conversion of remaining catalysts could justify the multiple, while further misses would pressure the stock toward the bear-case value of $128.

Implication

Monitor near-term catalysts closely; this ALS failure reduces upside optionality but does not alter the base-case thesis of Entresto offset by launch brands. Consider trimming positions if additional pipeline setbacks occur or if Q3 margin falls below 32%. Wait for either a pullback toward $140 for attractive entry or confirmation of Pluvicto mHSPC approval paired with at least one successful H2 pivotal readout before adding exposure.

Thesis delta

Thesis shifts slightly negative: ALS failure adds to a pattern of pipeline disappointments, though core catalysts remain intact. The WAIT rating is reinforced with lower confidence in back-half optionality. No change to valuation until Q3 results or major readouts clarify whether the premium multiple is justified.